Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Goodwill & Intangibles (2017 - 2024)

Historic Goodwill & Intangibles for Innate Pharma (IPHA) over the last 8 years, with Q2 2024 value amounting to $128149.6.

  • Innate Pharma's Goodwill & Intangibles fell 8696.74% to $128149.6 in Q2 2024 from the same period last year, while for Jun 2024 it was $128149.6, marking a year-over-year decrease of 8696.74%. This contributed to the annual value of $449994.5 for FY2023, which is 117576.63% up from last year.
  • Per Innate Pharma's latest filing, its Goodwill & Intangibles stood at $128149.6 for Q2 2024, which was down 8696.74% from $447591.0 recorded in Q4 2023.
  • In the past 5 years, Innate Pharma's Goodwill & Intangibles ranged from a high of $95.2 billion in Q2 2020 and a low of -$51.9 million during Q4 2020
  • In the last 5 years, Innate Pharma's Goodwill & Intangibles had a median value of $983298.6 in 2023 and averaged $10.6 billion.
  • In the last 5 years, Innate Pharma's Goodwill & Intangibles plummeted by 14835.36% in 2020 and then surged by 117002.04% in 2023.
  • Over the past 5 years, Innate Pharma's Goodwill & Intangibles (Quarter) stood at -$51.9 million in 2020, then surged by 197.41% to $50.6 million in 2021, then tumbled by 100.08% to -$41830.1 in 2022, then skyrocketed by 1170.02% to $447591.0 in 2023, then crashed by 71.37% to $128149.6 in 2024.
  • Its last three reported values are $128149.6 in Q2 2024, $447591.0 for Q4 2023, and $983298.6 during Q2 2023.